PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

NCT01374789 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped The study was terminated due to insufficient recruitment.

Conditions

Urinary Bladder Cancer

Interventions

DRUG: GemCis + Panitumumab
DRUG: GemCis

Sponsor

WiSP Wissenschaftlicher Service Pharma GmbH

Collaborators

[object Object]